期刊文献+

1例直肠癌患者药源性皮疹不良反应分析 被引量:1

下载PDF
导出
摘要 目的通过全程参与1例直肠癌患者的化疗过程,探讨药源性皮疹发生的原因及药师建议。方法通过与临床医生讨论患者病情、查房、文献检索等方式,探究导致该患者发生药源性皮疹的可能原因及治疗方案。结果充分考虑患者的用药情况,考虑西妥昔单抗可能是患者发生粉刺样皮疹的主因,通过对患者皮疹严重程度进行分级,采取相应的治疗措施。结论临床药师通过对肿瘤患者化疗的全程监护,体现了其在发生药源性不良反应后应起到的药学建议及药学监护的重要作用。
出处 《临床合理用药杂志》 2018年第3期102-103,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献2

二级参考文献16

  • 1安富荣,崔岚,戈升荣.治疗转移性结直肠癌新药——西妥昔单抗[J].中国新药杂志,2005,14(7):927-930. 被引量:20
  • 2Diaz Rubio E,Sastre J,Zaniboni A,et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase Ⅱ multicentric study[J]. Annals of Oncology, 1998, 9: 105 -108.
  • 3J onker D J, O' Callaghan C J, Karapetis C S, et al . Cetuximab for the treatment of colorectal cancer[J]. New Engl J Med, 2007,375:2040 -2048.
  • 4Diane B G, Delord J P, Philippe R, et al. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR[J]. Cancer Chemother Pharmacol, 2006,57 : 709-718.
  • 5Mahtani R L, Macdonald J S. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract[J]. Oncologist, 2008,13 : 39-50.
  • 6Tabernero J, Per Pfeiffer, Andres Cervantes. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? [J]. The Oncologist Gastrointestinal Cancer, 2008,13:113-119.
  • 7Pfeiffer P,Bjerregaard J K, Qvortrup C,et al. Simplification of cetuximab (Cet) administration: double dose every second week as a 60 minute infusion[J]. ASCO Meeting Abstracts, 2007,25 : 4133.
  • 8Tabernero J,Cervantes A,Martinelli E,et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pbarmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qlw) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC) [J]. ASCO Meeting Abstracts,2006,24 : 3085.
  • 9Cunningham D, Humbler Y,Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic cancer[J]. N Engl J Med,2004,351(4):337-345.
  • 10Souglakos J, Kalykaki A, Vamvakas L, et al. Phase Ⅱ trail of capectiabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin based chemotherapy[J]. Ann Oncol, 2007,18(2) : 305- 310.

共引文献1

同被引文献13

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部